Area of research
Rheumatology · Hematology
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research, Inflammasome and immune disorders, and Systemic Lupus Erythematosus Research.
Alzheimer's disease outlook: controversies and future directions
The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still’s disease
Items identified by expert physicians for the development of the criteria for the assessment of disease activity for adult-onset Still's disease: results of a web-based Delphi study informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for the assessment of disease activity in these patients
Distinct Natural Killer Cell Signature in Still Disease: Insights From a Multinational Immunome Project Consortium for Autoinflammatory Disorders
Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsis
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling
Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications†
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools.
PubMed 2020cited by 6position: middle
Prevotella copri in individuals at risk for rheumatoid arthritis
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab
OP0030 RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Regulation and function of interleukin‐36 cytokines
The interleukin (IL)-1 cytokine family – Balance between agonists and antagonists in inflammatory diseases
Distinct expression of interleukin (IL)-36<b>α, β</b> and <b>γ</b>, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease
Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
AB0451 NI-0101, a Monoclonal Antibody Targeting Toll Like Receptor 4 (TLR4) Being Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells